65695-05-8

Usage

Uses

Used in Organic Synthesis:
METHYL 4-[(Z)-AMINO(HYDROXYIMINO)METHYL]BENZOATE is used as a reagent for its ability to facilitate various chemical reactions, contributing to the synthesis of a wide range of organic compounds.
Used in Pharmaceutical Production:
As an intermediate, METHYL 4-[(Z)-AMINO(HYDROXYIMINO)METHYL]BENZOATE is instrumental in the manufacturing process of pharmaceuticals, playing a crucial role in the development of new drugs.
Used in Agrochemicals:
METHYL 4-[(Z)-AMINO(HYDROXYIMINO)METHYL]BENZOATE is also utilized as an intermediate in the production of agrochemicals, highlighting its broad applicability in different industries.
Used in Medicinal Chemistry and Drug Discovery:
Due to its potential biological activity and chemical properties, METHYL 4-[(Z)-AMINO(HYDROXYIMINO)METHYL]BENZOATE is employed as a key component in the field of medicinal chemistry and drug discovery, where it aids in the identification and development of novel therapeutic agents.
Used in the Synthesis of Complex Organic Molecules:
METHYL 4-[(Z)-AMINO(HYDROXYIMINO)METHYL]BENZOATE is used as a valuable building block for the synthesis of complex organic molecules, underlining its importance in advancing chemical research and innovation.

Upstream product

• 1129-35-7 4-cyanobenzoic acid methyl ester 
• 1443-80-7 4-cyanophenyl methyl ketone 
• 619-65-8 4-cyanobenzoic Acid 

Downstream Products

• 569685-49-0 3-[(4-carbomethoxy)phenyl]-5-(4-phenyl-5-trifluoromethyl-2-thienyl)-1,2,4-oxadiazole 
• 478489-13-3 5-(3-Chloro-thiophen-2-yl)-3-[4-(methyl carboxy)-phenyl]-[1,2,4]-oxadiazole 
• 1370330-82-7 methyl 4-(4,5-dihydro-5-oxo-4-(3-(5-oxo-3-phenyl-1,2,4-oxadiazol-4-yl)propyl)-1,2,4-oxadiazol-3-yl)benzoate 
• 1370330-83-8 C₁₈H₂₀N₄O₄ 
• 281234-03-5 methyl 4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoate 
• 340736-76-7 4-[5-(trifluoromethyl)-1,.2,4-oxadiazol-3-yl]benzoic acid 
• 340736-75-6 methyl 4-(5-phenyl-1,2,4-oxadiazol-3-yl)benzoate 
• 340736-72-3 methyl 4-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoate 
• 23610-05-1 4-[(Z)-N’-hydroxycarbamimidoyl]benzoic acid 
• 1092400-75-3 5-chloromethyl-3-(4-methoxycarbonylphenyl)-1,2,4-oxadiazole 
• 1092400-74-2 5-bromomethyl-3-(4-methoxycarbonylphenyl)-1,2,4-oxadiazole 
• 135321-84-5 methyl 4-(N-{[(2-methyl-2-propanyl)oxy]carbonyl}carbamimidoyl)benzoate 
• 791613-73-5 4-[5-(4-phenoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid methyl ester 

Relevant academic research and scientific papers

Cobalt-Catalyzed, Directed Intermolecular C-H Bond Functionalization for Multiheteroatom Heterocycle Synthesis: The Case of Benzotriazine

Transition-metal-catalyzed, directed intermolecular C-H bond functionalization is synthetically useful but heavily underexplored in multiheteroatom heterocycle synthesis. Herein we report a cobalt catalytic method for the formation of a three-nitrogen-bearing benzotriazine scaffold via the coupling of arylhydrazine and oxadiazolone. This synthetic protocol features a low-cost base metal catalyst, a maximum number of heteroatoms built into a heterocycle, a distinct synthetic logic for benzotriazines, a superior step economy, and a broad substrate scope.

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease

Using an iterative structure-activity relationship driven approach, we identified a CNS-penetrant 5-(trifluoromethyl)-1,2,4-oxadiazole (TFMO, 12) with a pharmacokinetic profile suitable for probing class IIa histone deacetylase (HDAC) inhibition in vivo.

AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

The present invention relates to aromatic ring or heteroaromatic ring compounds, a preparation method therefor and a medical use thereof. Particularly, the present invention relates to a compound as shown in general formula (I) and a preparation method th

SUBSTITUTED 4-[5-(BENZOFURAN-2-YL)-1,2,4-OXADIAZOL-3-YL]BENZOIC ACID COMPOUNDS FOR USE IN THERAPY FOR NEUROPATHIC PAIN

The present invention pertains generally to the field of therapy. More specifically, the present invention pertains to certain substituted 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid compounds (collectively referred to herein as BOBA compounds), and pharmaceutical compositions comprising those compounds, for use in a method of treatment or prevention of neuropathic pain. (Formula (A))

COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1), IMAGING OF S1P1, AND METHODS OF USE THEREOF

Among the various aspects of the present disclosure is the provision of a compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof. Provided are imaging agents for imaging S1P1 and S1P1 associated diseases, disorders, and conditions. Also provided are therapeutic compositions and methods for the treatment of S1P1 associated diseases, disorders, and conditions.

NOVEL OXADIAZOLES

The present invention relates to novel oxadiazoles of Formula I, wherein, R1, L1, A, L2 and R10 are as defined in the detailed description.

HETEROCYCLIC COMPOUNDS AS FUNGICIDES

The present invention relates to novel heterocyclic compound of Formula (I), (I) wherein, Het, L1, A, L2 and R12 are as defined in the detailed description, for use as fungicides.

A cascade process for directly converting nitriles (RCN) to cyanamides (RNHCN) via SO2F2-activated Tiemann rearrangement

A simple, mild and practical process for the direct conversion of nitriles to cyanamides was newly discovered and exhibited a wide substrate scope as well as great functional group-tolerability (36 examples). In this efficient strategy, the in situ generated amidoximes obtained from the reaction of nitriles with hydroxylamine subsequently underwent Tiemann rearrangement, producing the corresponding cyanamides with great isolated yields under SO2F2. Additionally, the control experiments reportedly shed light on the tentative mechanism involved in the formation and elimination of the key intermediate: a sulfonyl ester.

Syntheses and in vitro evaluation of new S1PR1 compounds and initial evaluation of a lead F-18 radiotracer in rodents

Thirteen new sphingosine-1-phosphate receptor 1 (S1PR1) ligands were designed and synthesized by replacing azetidine-3-carboxylic acid moiety of compound 4 with new polar groups. The in vitro binding potency of these new analogs toward S1PR1 was determined. Out of 13 new compounds, four compounds 9a, 10c, 12b, and 16b displayed high S1PR1 binding potency with IC50 values of 13.2 ± 3.2, 14.7 ± 1.7, 9.7 ± 1.6, and 6.3 ± 1.3 nM, respectively; further binding studies of these four ligands toward S1PR2-5 suggested they are highly selective for S1PR1 over other S1PRs. The radiosynthesis of the lead radiotracer [18F]12b was achieved with good radiochemical yield (～14.1%), high radiochemical purity (>98%), and good specific activity (～54.1 GBq/μmol, decay corrected to the end of synthesis, EOS). Ex vivo autoradiography and initial biodistribution studies in rodents were performed, suggesting that [18F]12b was able to penetrate the blood-brain barrier (BBB) with high brain uptake (0.71% ID/g at 60 min post-injection) and no defluorination was observed. In vitro autoradiography study in brain slices of lipopolysaccharides (LPS)-induced neuroinflammation mice indicated that SEW2871, a specific S1PR1 ligand was able to reduce the uptake of [18F]12b, suggesting [18F]12b has S1PR1 specific binding. These initial results suggested that [18F]12b has potential to be an F-18 labeled radiotracer for imaging S1PR1 in the brain of the animal in vivo.

CRYSTALLINE FORMS OF 4-(5-(4,7-DIMETHYLBENZOFURAN-2-YL)-1,2,4-OXADIAZOL-3-YL)BENZOIC ACID AND PROCESSES FOR THEIR PREPARATION

The present invention pertains generally to the field of therapeutic compounds, and more specifically to crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (referred to herein as "BHBA-001"), which, inter alia, is a (selective) retinoic acid receptor beta (RARβ) (e.g., RARβ2) agonist. The present invention also pertains to pharmaceutical compositions comprising such crystalline forms, and the use of such crystalline forms and compositions, both in vitro and in vivo, to (selectively) activate RARβ (e.g., RARβ2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RARβ (e.g., RARβ2), that are ameliorated by the activation of RARβ (e.g., RARβ2), etc., including, e.g., neurological injuries such as spinal cord injuries.